Home/Kyverna Therapeutics/Simona Skerjanec, PharmD, MBA
SS

Simona Skerjanec, PharmD, MBA

Chief Operating Officer

Kyverna Therapeutics

Kyverna Therapeutics Pipeline

DrugIndicationPhase
KYV-101Lupus Nephritis (Systemic Lupus Erythematosus)Phase 1/2
KYV-201Undisclosed autoimmune indicationPreclinical